These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 20594127

  • 21. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery.
    Meissner Y, Pellequer Y, Lamprecht A.
    Int J Pharm; 2006 Jun 19; 316(1-2):138-43. PubMed ID: 16675176
    [Abstract] [Full Text] [Related]

  • 22. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.
    Lamprecht A, Ubrich N, Yamamoto H, Schäfer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM.
    J Pharmacol Exp Ther; 2001 Nov 19; 299(2):775-81. PubMed ID: 11602694
    [Abstract] [Full Text] [Related]

  • 23. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
    El-Kamel AH, Abdel-Aziz AA, Fatani AJ, El-Subbagh HI.
    Int J Pharm; 2008 Jun 24; 358(1-2):248-55. PubMed ID: 18502065
    [Abstract] [Full Text] [Related]

  • 24. Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans.
    Goto T, Tanida N, Yoshinaga T, Sato S, Ball DJ, Wilding IR, Kobayashi E, Fujimura A.
    J Control Release; 2004 May 31; 97(1):31-42. PubMed ID: 15147802
    [Abstract] [Full Text] [Related]

  • 25. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.
    Xiao B, Merlin D.
    Expert Opin Drug Deliv; 2012 Nov 31; 9(11):1393-407. PubMed ID: 23036075
    [Abstract] [Full Text] [Related]

  • 26. Targeted drug delivery to mammalian mitochondria in living cells.
    Weissig V.
    Expert Opin Drug Deliv; 2005 Jan 31; 2(1):89-102. PubMed ID: 16296737
    [Abstract] [Full Text] [Related]

  • 27. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa.
    Collnot EM, Ali H, Lehr CM.
    J Control Release; 2012 Jul 20; 161(2):235-46. PubMed ID: 22306429
    [Abstract] [Full Text] [Related]

  • 28. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
    Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D.
    Gastroenterology; 2010 Mar 20; 138(3):843-53.e1-2. PubMed ID: 19909746
    [Abstract] [Full Text] [Related]

  • 29. Inflammatory bowel disorders: gene therapy solutions.
    Wirtz S, Neurath MF.
    Curr Opin Mol Ther; 2003 Oct 20; 5(5):495-502. PubMed ID: 14601518
    [Abstract] [Full Text] [Related]

  • 30. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis.
    Moulari B, Pertuit D, Pellequer Y, Lamprecht A.
    Biomaterials; 2008 Dec 20; 29(34):4554-60. PubMed ID: 18790531
    [Abstract] [Full Text] [Related]

  • 31. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model.
    Klein S, Stein J, Dressman J.
    J Pharm Pharmacol; 2005 Jun 20; 57(6):709-19. PubMed ID: 15969925
    [Abstract] [Full Text] [Related]

  • 32. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease.
    Ruiz JF, Radics G, Windle H, Serra HO, Simplício AL, Kedziora K, Fallon PG, Kelleher DP, Gilmer JF.
    J Med Chem; 2009 May 28; 52(10):3205-11. PubMed ID: 19397323
    [Abstract] [Full Text] [Related]

  • 33. Oral colon delivery of insulin with the aid of functional adjuvants.
    Maroni A, Zema L, Del Curto MD, Foppoli A, Gazzaniga A.
    Adv Drug Deliv Rev; 2012 May 01; 64(6):540-56. PubMed ID: 22086142
    [Abstract] [Full Text] [Related]

  • 34. Colonic drug delivery: an updated review.
    Shareef MA, Khar RK, Ahuja A, Ahmad FJ, Raghava S.
    AAPS PharmSci; 2003 May 01; 5(2):E17. PubMed ID: 12866944
    [Abstract] [Full Text] [Related]

  • 35. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis.
    De Vry CG, Prasad S, Komuves L, Lorenzana C, Parham C, Le T, Adda S, Hoffman J, Kahoud N, Garlapati R, Shyamsundar R, Mai K, Zhang J, Muchamuel T, Dajee M, Schryver B, McEvoy LM, Ehrhardt RO.
    Gut; 2007 Apr 01; 56(4):524-33. PubMed ID: 16950831
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Targeting strategies in cancer gene therapy.
    Wang JH, Liu XY.
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Apr 01; 35(4):311-6. PubMed ID: 12673383
    [Abstract] [Full Text] [Related]

  • 38. Regulation of intestinal epithelial function: a link between opportunities for macromolecular drug delivery and inflammatory bowel disease.
    Siccardi D, Turner JR, Mrsny RJ.
    Adv Drug Deliv Rev; 2005 Jan 06; 57(2):219-35. PubMed ID: 15555739
    [Abstract] [Full Text] [Related]

  • 39. Rapidly disintegrating oramucosal drug delivery technologies.
    Reddy D, Pillay V, Choonara YE, du Toit LC.
    Pharm Dev Technol; 2009 Jan 06; 14(6):588-601. PubMed ID: 19883248
    [Abstract] [Full Text] [Related]

  • 40. Mathematical modeling of drug delivery.
    Siepmann J, Siepmann F.
    Int J Pharm; 2008 Dec 08; 364(2):328-43. PubMed ID: 18822362
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.